A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib (NCT07623161)
A Phase 3, Double-Blind, Randomized Trial Evaluating the Efficacy and Safety of Elritercept (TAK-226) Compared to Placebo in Participants With Myelofibrosis and Anemia on Concurrent Ruxolitinib Therapy
🩺 Plain-English Summary (8th-Grade Level)
The main aim of this study is to find out how well elritercept works to improve anemia in participants with myelofibrosis (MF) who are taking ruxolitinib when compared to placebo. Other aims are to learn how elritercept improves anemia compared to placebo; to learn if elritercept reduces tiredness, improves symptoms related to MF, and helps participants do physical activities more easily. The study also aims to find out how elritercept affects the bone marrow, the spleen, and whether participants develop antibodies to the study drug. The study will also check how safe elritercept is compared to placebo, and if elritercept stays safe over a long period of time. Participants will receive study treatment for at least 9 months (36 weeks). After this period, participants who received placebo will have the option to switch to elritercept.
Who can join: Review the eligibility criteria below.
Location: Banner MD Anderson Cancer Center — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (195 Sites)
Showing the first 25 of 195 sites.
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Los Angeles Cancer Network — Glendale, California
- Cancer and Blood Specialty Clinic — Whittier, California
- MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- Advanced Research, LLC — Coral Springs, Florida
- Bioresearch Partners — Miami, Florida
- AdventHealth - Cancer Institute - Orlando — Orlando, Florida
- Florida Clinical Trials Group — Tamarac, Florida
- Moffit Cancer Center — Tampa, Florida
- Emory University — Atlanta, Georgia
- Tufts Medical Center — Boston, Massachusetts
- Washington University School of Medicine — St Louis, Missouri
- St. Vincent Regional Hospital Cancer Centers — Billings, Montana
- University of New Mexico Comprehensive Cancer Center — Albuquerque, New Mexico
- Memorial Sloan Kettering Cancer Center — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- Duke Blood Cancer Center — Durham, North Carolina
- Novant Health — Winston-Salem, North Carolina
- Cleveland Clinic — Cleveland, Ohio
- Oregon Health and Science University — Portland, Oregon
- Thomas Jefferson University — Philadelphia, Pennsylvania
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- Allegheny Health Network Cancer Institute - West Penn Hospital Location — Pittsburgh, Pennsylvania
- Medical University of South Carolina — Charleston, South Carolina
- Vanderbilt-Ingram Cancer Center (VICC)-Nashville — Nashville, Tennessee
📞 Contact the Study Coordinator
Phone: (877) 825-3327
Email: medinfoUS@takeda.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Myelofibrosis
- Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms — Birmingham, Alabama
- Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis — Calgary, Alberta
- Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis — Birmingham, Alabama
- Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) — Birmingham, Alabama
- A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis — Pasadena, California
- A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) — Newport Beach, California
Explore by condition: All Myelofibrosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.